Incretin mimetics are ideal candidate therapies for T2D as they exert their actions specifically during hyperglycaemic conditions and have the additional capacity to regulate body weight ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
But be warned : This requires continuous use to maintain results
patients without T2DM: SMD 0.82
Overview of ferroptosis: mechanisms and therapeutic potential Ferroptosis is characterized by the accumulation of lipid peroxides, distinguishing it from apoptosis, necrosis, and autophagy [85]
When possible, provide a lighter portion option of the same entre that was originally offered